4 hrs ago
Mylan Commences Clinical Trials for Generic Versions of Advair Diskus and Insulin Analog to Lantus
Mylan today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus. In October 2014, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
Fri Sep 12, 2014
European Commission Grants Lilly and Boehringer Ingelheim's Insulin Glargine Product Marketing in EU
The European Commission granted marketing authorization for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents, and children aged two years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim Alliance.
Wed Sep 10, 2014
Indianapolis Business News
Lilly receives European marketing OK for new insulin
European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent-infringement litigation with French rival Sanofi.
Tue Sep 09, 2014
Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce...
Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50 th EASD Annual Meeting 28 abstracts presented, including data on empagliflozin, an SGLT2 inhibitor recently approved in the European Union and in the US as Jardiance A )--Data to be presented at the European Association for the Study of Diabetes Annual Meeting in Vienna, Austria, will add to the extensive clinical evidence supporting the efficacy and safety profile of the diabetes portfolio from the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. In addition, physician insights will be presented from IntroDiaa , the largest global survey of its kind in Type 2 Diabetes .
Mon Sep 08, 2014
The Motley Fool
3 Reasons Sanofi's Stock Could Fall
Consequently, its shares have under-performed both the broader markets and the healthcare sector in general, as shown by the chart below. To improve top line growth and return to profitability, Sanofi's CEO Christopher Viehbacher has increasingly leaned on the company's clinical pipeline to replace lost revenues.
New insulin glargine 300 U/mL versus glargine 100 U/mL in people with ...
New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial . To compare efficacy and safety of new insulin glargine 300 U/mL with glargine 100 U/mL in people with type 2 diabetes using basal insulin plus oral antihyperglycemic drugs .
Thu Sep 04, 2014
The Indianapolis Star
Eli Lilly insulin tops Lantus in two tests
Eli Lilly insulin tops Lantus in two tests It's rare for new bio-engineered insulins to show notably better treatment differences against the market leader Check out this story on IndyStar.com: http://indy.st/1rOmPHL Eli Lilly and Co. corporate headquarters at Delaware and McCarty streets in Downtown Indianapolis.
Applied Clinical Trials
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority...
Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators Lilly expects U.S. and European regulatory submissions by end of Q1 2015 Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus in Phase III Trials in Patients with Type 1 Diabetes /PRNewswire/ -- Eli Lilly and Company's basal insulin peglispro demonstrated a statistically significant lower hemoglobin A1c compared with insulin glargine at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. Patients in these trials were also taking mealtime insulin.
Tue Sep 02, 2014
Sanofi Should Be Part Of Your Portfolio If You Want Higher Returns
Sanofi had a decent second quarter. The company's sales remained stable at $10.65 billion compared with $10.56 billion quarter over quarter.
Fri Aug 22, 2014
FDA Grants Tentative Approval for Lilly and Boehringer...
INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration today granted tentative approval for Basaglara , which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes.
Thu Aug 21, 2014
Zealand Pharma A/S - Interim report for H1 2014
Ex-US market roll-out of Lyxumia by Sanofi continues with several new launches in Q2 2014 and additional launches expected over the rest of the year -- Broad-based pipeline progress - internal and external -- LixiLan Phase III trials advanced by Sanofi with completion expected in H2 2015 -- Plans on track for US filing of Lyxumia in Summer 2015 and ... (more)
Mon Aug 18, 2014
FDA Grants Tentative Approval for Lilly and Boehringer...
Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company and Boehringer Ingelheim's basal insulin, which is intended to provide long-lasting blood sugar control in between meals and during the night.1 Basaglar has the same amino acid sequence as the currently marketed insulin glargine product and was ... (more)
Eli Lilly: Strong Future Prospects Will Restore The Company's Financials
Patent expiries of Cymbalta and Evista have strangled Eli Lilly's quarterly performance this time.